Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | Emerging anti-CD20 monoclonal antibodies as first-line therapy in elderly CLL

Paolo Ghia • 12 Jun 2015
EHA 2015
Chronic Lymphocytic Leukemia Antibodies Obinutuzumab Ofatumumab

At the 20th Congress of the European Hematology Association (EHA), Paolo Ghia, MD, PhD, of Università Vita-Salute San Raffaele, Milan, Italy, discusses the results of clinical trials of anti-CD20 monoclonal antibodies in combination with chloramubucil, obinutuzumab plus chloramubucil and ofatumumab plus chlorambucil, for first-line therapy in older patients with chronic lymphocytic leukemia (CLL).

More from Paolo Ghia

1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
MBL: biology, classification & the possibility of early interception
Andrew Rawstron et al. • 25 Mar 2024
2:20
Monoclonal B-cell lymphocytosis: at a crossroad between disease and senescence
Paolo Ghia • 8 Dec 2023
3:00
Five-year follow-up of the CAPTIVATE trial: ibrutinib retreatment in patients with CLL
Paolo Ghia • 8 Dec 2023

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals